Your browser doesn't support javascript.
loading
1,2,4-Triazole-3-Thione Analogues with a 2-Ethylbenzoic Acid at Position 4 as VIM-type Metallo-ß-Lactamase Inhibitors.
Verdirosa, Federica; Gavara, Laurent; Sevaille, Laurent; Tassone, Giusy; Corsica, Giuseppina; Legru, Alice; Feller, Georges; Chelini, Giulia; Mercuri, Paola Sandra; Tanfoni, Silvia; Sannio, Filomena; Benvenuti, Manuela; Cerboni, Giulia; De Luca, Filomena; Bouajila, Ezeddine; Vo Hoang, Yen; Licznar-Fajardo, Patricia; Galleni, Moreno; Pozzi, Cecilia; Mangani, Stefano; Docquier, Jean-Denis; Hernandez, Jean-François.
Afiliação
  • Verdirosa F; Dipartimento di Biotecnologie Mediche, Università di Siena, 53100, Siena, Italy.
  • Gavara L; IBMM, CNRS, Univ Montpellier, ENSCM, Montpellier, France.
  • Sevaille L; IBMM, CNRS, Univ Montpellier, ENSCM, Montpellier, France.
  • Tassone G; Dipartimento di Biotecnologie, Chimica e Farmacia, Università di Siena, 53100, Siena, Italy.
  • Corsica G; Dipartimento di Biotecnologie Mediche, Università di Siena, 53100, Siena, Italy.
  • Legru A; IBMM, CNRS, Univ Montpellier, ENSCM, Montpellier, France.
  • Feller G; Laboratoire de Biochimie, Centre d'Ingénierie des Protéines-InBioS, Université de Liège, Allée du 6 août B6, Sart-Tilman, 4000, Liège, Belgium.
  • Chelini G; Dipartimento di Biotecnologie Mediche, Università di Siena, 53100, Siena, Italy.
  • Mercuri PS; Laboratoire des Macromolécules Biologiques, Centre d'Ingénierie des Protéines-InBioS, Université de Liège, Institute of Chemistry B6a, Sart-Tilman, 4000, Liège, Belgium.
  • Tanfoni S; Dipartimento di Biotecnologie Mediche, Università di Siena, 53100, Siena, Italy.
  • Sannio F; Dipartimento di Biotecnologie Mediche, Università di Siena, 53100, Siena, Italy.
  • Benvenuti M; Dipartimento di Biotecnologie, Chimica e Farmacia, Università di Siena, 53100, Siena, Italy.
  • Cerboni G; Dipartimento di Biotecnologie Mediche, Università di Siena, 53100, Siena, Italy.
  • De Luca F; Dipartimento di Biotecnologie Mediche, Università di Siena, 53100, Siena, Italy.
  • Bouajila E; IBMM, CNRS, Univ Montpellier, ENSCM, Montpellier, France.
  • Vo Hoang Y; IBMM, CNRS, Univ Montpellier, ENSCM, Montpellier, France.
  • Licznar-Fajardo P; HSM, Univ Montpellier, CNRS, IRD, CHU Montpellier, Montpellier, France.
  • Galleni M; Laboratoire des Macromolécules Biologiques, Centre d'Ingénierie des Protéines-InBioS, Université de Liège, Institute of Chemistry B6a, Sart-Tilman, 4000, Liège, Belgium.
  • Pozzi C; Dipartimento di Biotecnologie, Chimica e Farmacia, Università di Siena, 53100, Siena, Italy.
  • Mangani S; Dipartimento di Biotecnologie, Chimica e Farmacia, Università di Siena, 53100, Siena, Italy.
  • Docquier JD; Dipartimento di Biotecnologie Mediche, Università di Siena, 53100, Siena, Italy.
  • Hernandez JF; Centre d'Ingénierie des Protéines-InBioS, Université de Liège, 4000, Liège, Belgium.
ChemMedChem ; 17(7): e202100699, 2022 04 05.
Article em En | MEDLINE | ID: mdl-35050549
ABSTRACT
Metallo-ß-lactamases (MBLs) are increasingly involved as a major mechanism of resistance to carbapenems in relevant opportunistic Gram-negative pathogens. Unfortunately, clinically efficient MBL inhibitors still represent an unmet medical need. We previously reported several series of compounds based on the 1,2,4-triazole-3-thione scaffold. In particular, Schiff bases formed between diversely 5-substituted-4-amino compounds and 2-carboxybenzaldehyde were broad-spectrum inhibitors of VIM-type, NDM-1 and IMP-1 MBLs. Unfortunately, these compounds were unable to restore antibiotic susceptibility of MBL-producing bacteria, probably because of poor penetration and/or susceptibility to hydrolysis. To improve their microbiological activity, we synthesized and characterized compounds where the hydrazone-like bond of the Schiff base analogues was replaced by a stable ethyl link. This small change resulted in a narrower inhibition spectrum, as all compounds were poorly or not inhibiting NDM-1 and IMP-1, but showed a significantly better activity on VIM-type enzymes, with Ki values in the µM to sub-µM range. The resolution of the crystallographic structure of VIM-2 in complex with one of the best inhibitors yielded valuable information about their binding mode. Interestingly, several compounds were shown to restore the ß-lactam susceptibility of VIM-type-producing E. coli laboratory strains and also of K. pneumoniae clinical isolates. In addition, selected compounds were found to be devoid of toxicity toward human cancer cells at high concentration, thus showing promising safety.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tionas / Inibidores de beta-Lactamases Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tionas / Inibidores de beta-Lactamases Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article